Immutep Ltd Stock Australian S.E.
Equities
AU000000PRR9
Biotechnology & Medical Research
Sales 2024 * | 4.14M 2.7M | Sales 2025 * | 17.82M 11.63M | Capitalization | 499M 326M |
---|---|---|---|---|---|
Net income 2024 * | -44M -28.71M | Net income 2025 * | -42M -27.41M | EV / Sales 2024 * | 102 x |
Net cash position 2024 * | 75.11M 49.02M | Net cash position 2025 * | 61.67M 40.25M | EV / Sales 2025 * | 24.6 x |
P/E ratio 2024 * |
-11.1
x | P/E ratio 2025 * |
-11.7
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.19% |
Managers | Title | Age | Since |
---|---|---|---|
Marc Voigt
CEO | Chief Executive Officer | 51 | 10-12-31 |
David Fang
DFI | Director of Finance/CFO | - | 18-02-28 |
Florian Vogl
CTO | Chief Tech/Sci/R&D Officer | - | 23-04-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Russell Howard
CHM | Chairman | 74 | 13-05-07 |
Marc Voigt
CEO | Chief Executive Officer | 51 | 10-12-31 |
Anne Anderson
BRD | Director/Board Member | - | Feb. 13 |
1st Jan change | Capi. | |
---|---|---|
+0.67% | 42.4B | |
+47.02% | 40.04B | |
-6.20% | 28.31B | |
+6.55% | 24.94B | |
-21.66% | 18.96B | |
+29.96% | 12.3B | |
-1.57% | 11.95B | |
+16.03% | 11.32B | |
-4.80% | 11.55B |